Physician profile
Yu Guan
NPI 1801091236
$11,985.78
in general payments reported to CMS, 2019-2025
45 companies · $1,323 in 2025
The $1,323 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,494 · 2020: $1,304 · 2021: $1,862 · 2022: $1,500 · 2023: $2,356 · 2024: $2,147 · 2025: $1,323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,705 · Education: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,704.60 |
| Education | $121.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,722.28 | 2019-2025 | Farxiga, Airsupra |
| Abbvie INC. | $1,598.66 | 2019-2025 | |
| Amgen INC. | $1,208.73 | 2019-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $1,082.59 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $833.40 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $798.92 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $744.58 | 2019-2025 | Jardiance, Spiriva Respimat, Synjardy |
| Pfizer INC. | $590.11 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $416.02 | 2019-2024 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $346.26 | 2019-2025 | Trintellix |
| Merck Sharp & Dohme LLC | $298.55 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Astellas Pharma US INC | $267.96 | 2019-2024 | Veozah, Myrbetriq |
| Shield Therapeutics INC | $216.78 | 2023-2024 | Accrufer |
| Amarin Pharma, INC. | $202.70 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $184.51 | 2022 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yu Guan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.